Yes, we agree that there should be some regulatory provisions that allow Canadians to have the information they need to make an informed decision when they're choosing a product, in case there is no health care provider available to them to identify those issues.
Another important thing is that these products are relatively safe. There is still a risk. The most important thing is that sometimes these risks are not available before these products get to the public. That's what we are advocating. Postmarket surveillance is really important. If a really serious adverse effect is happening because of a natural product, there should be a regulatory authority to collect that data, analyze that data and also inform Canadians about that serious adverse effect.